Current evidence on its potential effect on miR-27a expression, which represses DPD activity, leading to DPD deficiency and increased fluoropyrimidine-associated toxicity risk, is scarce and inconsistent. This evidence concerns the gene DPYD and dihydropyrimidine dehydrogenase deficiency.